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Abstract
Purpose Few prospective follow-up studies evaluating the
use of peripherally inserted central catheters (PICCs) to deliv-
er chemotherapy and/or home parenteral nutrition (HPN) have
focused exclusively on oncology outpatients. The aim of this
prospective study was to assess the reliability and the safety of
PICCs over a 5-year use in non-hospitalized cancer patients
requiring long-term intravenous therapies.
Methods Since June 2008, all adult oncology outpatient can-
didates for PICC insertion were consecutively enrolled and the
incidence of catheter-related complications was investigated.
The follow-up continued until the PICC removal.
Results Two hundred sixty-nine PICCs in 250 patients (98 %
with solid malignancies) were studied, for a total of 55,293
catheter days (median dwell time 184 days, range 15–1,384).
All patients received HPN and 71 % received chemotherapy
during the study period. The incidence of catheter-related
bloodstream infections (CRBSIs) was low (0.05 per 1,000
catheter days), PICC-related symptomatic thrombosis was
rare (1.1 %; 0.05 per 1,000 catheter days), and mechanical
complications were uncommon (13.1 %; 0.63 per 1,000 cath-
eter days). The overall complication rate was 17.5 % (0.85 per
1,000 catheter days) and PICCs were removed because of
complications only in 7 % of cases. The main findings of this
study were that, if accurately managed, PICCs can be safely
used in cancer patients receiving chemotherapy and/or HPN,
recording a low incidence of CRBSI, thrombosis, and me-
chanical complications; a long catheter life span; and a low
probability of catheter removal because of complications.
Conclusions Our study suggests that PICCs can be success-
fully utilized as safe and long-lasting venous access devices in
non-hospitalized cancer patients.
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Introduction
In non-hospitalized cancer patients, the presence of a venous
access device (VAD) is important in the anticancer treatment
period for chemotherapy [1] or home parenteral nutrition
(HPN) [2], as well as in the advanced phase for palliative care
[3]. Choosing the appropriate device for the oncology patient
should need a proactive vascular access planning; however, the
choice of VAD still largely depends on the therapies’ expected
duration or on the clinical experience of the provider [1].
Since the 1970s, peripherally inserted central catheters
(PICCs) have been available, but only in the last 20 years has
their use dramatically increased in several clinical settings
[4–16]. The use of PICCs has many advantages over other
long-term VADs [17, 18]. First is their ease of insertion due to
the placement into a peripheral vein—a safer approach—with
the benefit of a central tip location appropriate for any osmo-
larity and pH infusions (e.g., chemotherapy drugs,
P. Cotogni (*)
Anesthesiology and Intensive Care, Unit of Parenteral Nutrition in
Oncology, Department of Medicine, S. Giovanni Battista Hospital,
University of Turin, Via Giovanni Giolitti 9, 10123 Turin, Italy
e-mail: paolo.cotogni@unito.it
C. Barbero
Department of Cardiovascular and Thoracic Surgery, S. Giovanni
Battista Hospital, University of Turin, Turin, Italy
C. Garrino :C. Degiorgis : B. Mussa
Central Venous Access Team, S. Giovanni Battista Hospital,
University of Turin, Turin, Italy
A. De Francesco
Division of Clinical Nutrition, Department of Medicine, S. Giovanni
Battista Hospital, University of Turin, Turin, Italy
M. Pittiruti
Department of Surgery, Catholic University Hospital, Rome, Italy
Support Care Cancer (2015) 23:403–409
DOI 10.1007/s00520-014-2387-9
# The Author(s) 2014. This article is published with open access at Springerlink.com
hyperosmolar parenteral nutrition (PN) solutions, and long-
term antibiotics). PICC placement under ultrasound guidance
can be carried out with risks of pneumothorax or hemothorax
virtually nonexistent in addition to a low risk of primary mal-
position [2, 19]. Moreover, their insertion turns out to be less
expensive, as they are usually placed by trained nurses—in an
ambulatory setting or bedside—without radiographic or surgi-
cal means [6, 17, 20, 21]. Also, patients at high risk of hemor-
rhage needing a central VAD are eligible for PICC insertion
with no risk of local bleeding [1, 2]. Finally, the ease of removal
in case of complications offers an adjunctive advantage.
Since 2006, a systematic review of 200 published prospec-
tive studies of infection associated with the various types of
VADs in adults depicted that PICCs (n=2,813; 98,702 days)
were at low risk for catheter-related bloodstream infections
(CRBSIs) (0.8–1.2 per 1,000 catheter days) in outpatients
[13]. Nevertheless, some physicians are still concerned about
potential risks associated with the use of PICCs in oncology
patients requiring prolonged intravenous therapies due to the
reported rates of CRBSIs and thrombosis in earlier PICC
experiences [22] and the immunocompromised and
prothrombotic tendency of the cancer population [23].
Few prospective follow-up studies evaluating the use of
PICCs to deliver chemotherapy and/or HPN have focused
exclusively on oncology outpatients. The aim of this study
was to assess the reliability and the safety of PICCs over a 5-
year use in non-hospitalized cancer patients requiring long-
term intravenous therapies.
Patients and methods
Our study was a prospective observational study carried out
from June 1, 2008, through May 31, 2013, in a 1,200-bed
university hospital. The Ethics Committee approved the study
protocol. Awritten informed consent was obtained from each
patient. All adult cancer patients with a PICC inserted during
the study period were consecutively enrolled and their follow-
up continued until the PICC removal. Our unit maintains an
ongoing prospective database and coordinates the data gath-
ering related to outpatients and is therefore able to determine
the true incidence of complications.
Three types of PICCs were used: (1) 4 Fr single-lumen
silicone with a valved tip (Groshong PICC; Bard Access
Systems, Salt Lake City, UT), (2) 4–5 Fr single-lumen poly-
urethane (Vascu-PICC; MedComp, Harleysville, PA), and (3)
4–5 Fr single-lumen polyurethane power-injectable (Pro-
PICC; MedComp and Health Line, San Francisco, CA). All
PICCs were inserted by specifically trained nurses or physi-
cians of the hospital Central Venous Access Team in a room
exclusively dedicated to PICC placement. PICCs were
inserted with maximal barrier precautions and skin antisepsis
with 2 % chlorhexidine using ultrasound-guided venipuncture
of the upper midarm and sutureless devices for securing the
catheter. The appropriate central position of the catheter tip
(i.e., close to the cavoatrial junction) was consistently verified,
either by the intracavitary electrocardiography (EKG) method
[24] during the procedure or by chest X-ray after the proce-
dure. According to current guidelines [25, 26], routine phar-
macological prophylaxis of PICC-related venous thrombosis
was not adopted. All patients were screened at least once a
year by local ultrasound examination or Doppler technology
and echocardiography.
In our hospital, HPN was not routine practice neither in all
cancer patients nor the subset receiving chemotherapy.
According to our regional policy, an oncologic patient should
receiveHPNwhenmeeting all the following criteria: (1) proven
failure to meet nutrition requirements by the oral or enteral
route, with impending risk of death due to malnutrition; (2) life
expectancy >2 months; (3) Karnofsky performance status ≥50;
(4) control or absence of pain; (5) absence of severe organ
dysfunctions; (6) written informed consent confirming that the
patient will accept this modality of nutrition support; (7) ap-
proval by the physician responsible for HPN, by the oncologist,
and by the general practitioner; (8) presence of environmental
conditions compatible with HPN; (9) availability of a dedicated
in-home caregiver; (10) and availability of a nursing team
dedicated to the patient home care, as provided by the
Regional Public Health Service. HPN was defined as patients
receiving a PN bag at home on a 10- to 14-h per day basis.
Chemotherapy was defined as patients receiving intravenous
or oral anticancer chemotherapeutic drugs. Chemotherapy regi-
menswere administered by oncologists according to the patients’
need (perioperative, adjuvant, or palliative chemotherapy) fol-
lowing the European Society for Medical Oncology (ESMO)
Clinical Practice Guidelines (www.esmo.org). A detailed
description of the chemotherapy regimens adopted in the
different sites and stages of the tumors is beyond the aims of
this paper. In those patients who were receiving HPN and
intravenous chemotherapy, the PICC was used for both the
therapies but never at the same time.
In all patients, maintenance/care of PICC was carried out
by specifically trained nurses through home visits initially
every day for 2–3 weeks and at least every 7 days thereafter,
according to the recommendations of our regional health
service. A strict policy of hand washing and of environmental
hygiene was observed by nurses and caregivers at home.
Similarly, an appropriate asepsis when managing the PICC;
a strict policy for flushing the catheter with normal saline
before and after use, with the pulsating “push/pause” plus
positive-pressure method [27]; and the use of transparent
dressings were adopted. The lines were also used for drawing
blood and flushed with 20 ml of normal saline post-blood
draw. No heparin lock was used; PICCs were flushed with the
pulsating push/pause plus positive-pressure method and were
locked with 10–20 ml of normal saline [28].
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Diagnosis of local infection and of CRBSI was carried out
according to the guidelines issued by the Society for Healthcare
Epidemiology of America-Infectious Diseases Society of
America (IDSA) [29, 30]. Specifically, the clinical definition
of CRBSI was a bacteremia or fungemia in a patient who has an
intravascular device and more than one positive blood culture
result obtained from the peripheral vein, clinical manifestations
of infection, and no apparent source for bloodstream infection
(BSI) (with the exception of the VAD), plus simultaneous
quantitative cultures of blood with a ratio of >3:1 colony-
forming units/milliliter of blood (catheter vs. peripheral blood),
or differential time to positivity (growth in a culture of blood
obtained through a catheter hub is detected by an automated
blood culture system at least 2 h earlier than a culture of
simultaneously drawn peripheral blood of equal volume) [29].
Management of CRBSI (by removal and/or at least 10–
14 days of systemic antibiotic treatment plus antibiotic lock
therapy, when recommended) closely followed the IDSA guide-
lines [30]. Catheter-related venous thrombosis was diagnosed
and treated according to guidelines [2, 25, 26]; only symptomatic
thrombosis was considered (i.e., local pain, edema, and signs
suggesting thrombosis, later confirmed by ultrasound examina-
tion or Doppler technology). Mechanical complications were
managed according to current guidelines [2, 27, 28].
Causes of PICC removal due to complications included
local infection; CRBSI with indication for PICC removal
because of failure of or contraindication to conservative treat-
ment [30]; PICC-related venous thrombosis associated with
catheter malfunction [25, 26]; rupture of the external segment
of the catheter, if impossible to repair; complete or partial
(>4 cm) dislocation of the catheter; and lumen occlusion
resistant to clearance techniques/treatments.
Statistical analysis
The duration of PICCs was expressed as median (range). The
rates of complications were expressed per 1,000 catheter days
(incidence rate) and/or as a percentage of total PICCs.
Complication rates were compared using Fisher’s exact or
χ2 tests adjusted for catheter days. The level of significance
was defined as a P value <0.05. All analyses were carried out
using SPSS 17.0 (SPSS, Inc., an IBMCompany, Chicago, IL).
For the analysis, each PICC placement was counted as a new
event. This case series included the reported PICCs in our
previous study [31].
Results
Since June 1, 2008, through May 31, 2013, 250 non-
hospitalized adult cancer patients (98 % with solid malignan-
cies, mainly gastrointestinal tumors) were consecutively
enrolled in this study (Table 1). In 93 % of cases, the patients
were in stage III or IV according to TNM. One hundred
seventy-seven patients (71 %) received chemotherapy during
the study period. All patients received HPN, 213 (85 %) for
more than 90 % of the PICC life span. All of them were
followed up until PICC removal or until a patient deceased
and no one was lost at follow-up.
Two hundred sixty-nine PICCs were studied, for a total of
55,293 catheter days (median dwell time 184 days). With
respect to device characteristics, 226 were 4 Fr (84 %) and
108 (40 %) were power-injectable PICCs. PICCs were most
commonly inserted in the right arm (210; 78 %), in the basilic
vein (191; 71 %), and by nurses (199; 74 %).
Complications and outcomes are shown in Table 2. The
incidence of CRBSIs was low (0.05 per 1,000 catheter days),
mechanical complications were uncommon (13.1 %; 0.63 per
1,000 catheter days), and PICC-related symptomatic throm-
bosis was rare (1.1 %; 0.05 per 1,000 catheter days). The three
episodes of CRBSI occurred 22, 79, and 127 days after PICC
insertion, while the three episodes of thrombosis occurred 9,
16, and 21 days after PICC insertion. The overall complication
rate was 17.5 % (0.85 per 1,000 catheter days) and PICCs
were removed because of complications in 7 % of cases. The
rate of complications was not significantly different between
the three types of PICCs. Because of complications, no pa-
tients required hospitalization. With respect to microbiology,
CRBSIs were caused by coagulase-negative staphylococci
(two cases) and Escherichia coli (one case). In two cases of
CRBSI, PICCs were removed.
During this period, seven cancer patients had a PICC in site
for more than 2 years—with a total dwell time of 6,499
catheter days—with two PICCs lasting more than 3 years.
Table 3 shows the main characteristics of these patients.
Table 1 Characteristics of the patient population
N 250
Female gender, n (%) 127 (51)
Age (years), median (range) 65 (26–85)
Tumor site, n (%)
Stomach 74 (30)
Pancreas/biliary system 52 (21)
Colon/rectum 35 (14)
Esophagus 21 (8)
Ovary 17 (7)
Others 51 (20)
Stage, n (%)
II 17 (7)
III 43 (17)
IV 190 (76)
ECOG PS, median (range) 1 (0–2)
ECOG Eastern Cooperative Oncology Group, PS performance status
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Discussion
Cancer, HPN, and chemotherapy are recognized risk factors
for the development of severe complications (i.e., CRBSI and
thrombosis) and mechanical complications (i.e., lumen occlu-
sion, dislocation) in patients with a central VAD [1, 6, 7,
31–33]. The main finding of this study was that, if inserted
and managed according to proper evidence-based protocols,
PICCs can be safely used in cancer patients receiving chemo-
therapy and/or HPN, with a low incidence of CRBSI, throm-
bosis, and mechanical complications; a long catheter life span;
and a low probability of catheter removal because of
complications.
Based on a large and growing clinical experience, PICCs
started to be used frequently in cancer patients [3, 15, 17, 18,
23, 31, 34–39]. However, conflicting evidences on the rate of
PICC-related complications were reported in literature in on-
cology settings. Walshe et al. in 2002 documented an overall
complication rate of 10.9 per 1,000 catheter days in 351
patients (58 % outpatients) with 366 PICCs used for multiple
purposes (10,562 catheter days) [17], but argued for continued
PICC use in the cancer population. Cheong et al. in 2004, in a
small-size retrospective study (17 patients, 27 PICCs used for
chemotherapy), found an overall complication rate of 40.7 %
catheter days [23]. Actually, at the same institution 2 years
after the introduction of proper strategies to reduce PICC
complications, Yap et al. described in 73 similar patients with
88 PICCs a reduced overall complication rate of 15.9 % or 2
per 1,000 catheter days (P=0.006) [18]. Worth et al. in 2009
described a CRBSI rate of 6.6 and a thrombosis rate of 7.7 per
1,000 catheter days in oncohematological patients with 75
PICCs [36]. Differently, in a 2011 study regarding 807
PICCs used for chemotherapy or autologous stem cell proce-
dures in 727 patients with solid and hematogenous tumors,
Mollee et al. reported a rate of BSI (1.81 per 1,000 catheter
days over 41,876 catheter days) and concluded suggesting the
use of PICCs in such population [38]. In our study, the overall
complication rate was 17.5 %, but just 0.85 per 1,000 catheter
days due to the long median PICC duration (about 6 months);
moreover, PICCs were removed because of complications
only in 7 % of cases.
The rate of central catheter-related complications has
changed: CRBSIs, thrombosis, and mechanical complications
are lower than those reported in the last 20 years. Nowadays,
the goal of “near zero” CRBSI—the most feared complica-
tion—is no longer a dream [40, 41]. In recent years, several
technological novelties have considerably improved the safety
of PICCs (i.e., ultrasound-guided venipuncture of the upper
midarm, novel materials, sutureless devices for catheter se-
curement), whereas new policies have successfully decreased
the overall risk of complications (well-defined “bundles” of
evidence-based interventions, strict policies on hand washing,
proper skin antisepsis, training of healthcare professionals,
etc.) [14, 18, 37]. In oncology patients, Tian et al. reported
that after helpful interventions in reducing complications, the
overall PICC complication rate has decreased from 30 to 11%
(P=0.0004) [37]. Harnage in a medical center—adopting the
multimodality “bundle” for infection prevention—has report-
ed for a huge number of PICCs (i.e., 12,577) an incidence of
zero BSI per 1,000 catheter days for a period of 7 years [14].
Recently, a prospective study—with a large proportion of
oncologic patients enrolled—has reported zero CRBSI and
zero thrombosis in HPN patients with 48 PICCs [15].
Similarly, a prospective study at our institution with a small
number of PICCs and a limited follow-up (65 PICCs and
18 months, respectively) reported the same results in cancer
patients [31].
A critical issue is the scenario where the PICC is used
because the in-hospital setting is markedly different from the
out-hospital one. Chopra et al. clearly demonstrated that
PICCs are associated with a lower risk of BSI (0.5 %) than
central venous catheters (2.1 %) in outpatients [42].
Conversely, contradictory data on the rate of PICC-related
BSI were described for inpatients (mainly, intensive care unit
patients) [16]. In this study, a low incidence of CRBSI was
reported (0.05 per 1,000 catheter/days) in non-hospitalized
cancer patients. The following key components of our PICC
Table 2 Complications of 269 peripherally inserted central catheters
(PICCs)
Duration (day), median (range) 184 (15–1,384)
Infectious complications
Local infection, n 6
n/1,000 catheter days 0.11
CRBSI, n 3
n/1,000 catheter days 0.05
Total, n (%) 9 (3.3)
Venous thrombosis, n (%) 3 (1.1)
n/1,000 catheter days 0.05
Mechanical complications
Catheter dislocation, n (%) 19 (7.1)
Rupture of external tract, n (%) 4 (1.5)
Lumen occlusion, n (%) 12 (4.5)
Total, n (%) 35 (13.1)
n/1,000 catheter days 0.63
Overall complications, n (%) 47 (17.5)
n/1,000 catheter days 0.85
Causes of removal, n (%)
Catheter complications 19 (7)
End of IV therapy 85 (32)
Death 165 (61)
Removal ratioa, n (%) 19/47 (40)
CRBSI catheter-related bloodstream infection, IV intravenous
a Ratio between number of removals because of catheter complications
and number of total complications
406 Support Care Cancer (2015) 23:403–409
management may as well have been the reason for this result:
(a) the consistent use of ultrasound guidance and sutureless
devices [31], (b) the exclusive use of single-lumen PICCs
[16], and (c) the consistent use of maximal barrier precautions
and skin antisepsis with 2 % chlorhexidine [30, 37].
Earlier studies have reported risks of symptomatic catheter-
related thrombosis as high as 28 %, but more recent studies
suggest a much lower incidence at 5% or less [17, 43, 44]. Lee
et al. reported in a prospective study over 76,713 patient days
(500 cancer patients, 444 VADs with 65 % PICCs) that the
incidence of symptomatic catheter-related thrombosis was
4.3 % or 0.3 per 1,000 catheter days [44]. Chopra et al. have
recently reported in a meta-analysis that PICCs were associ-
ated with a higher risk of deep vein thrombosis in cancer
patients [45]. Nevertheless, Tian et al. in a study on cancer
patients with 267 PICCs reported that the incidence of throm-
bosis has decreased from 2.9 to 0.61 % using relatively simple
and inexpensive interventions [37].
In this study, a low incidence of symptomatic PICC-related
thrombosis was reported (1.1 %; 0.05 per 1,000 catheter
days). This result was probably due to several factors: (a) the
consistent use of ultrasound guidance for PICC placement, (b)
the consistent choice of deep veins of the upper midarm
(mainly, the basilic vein), (c) the systematic choice of a vein
with an appropriate ratio between catheter diameter and vein
diameter (i.e., 1:3 ratio), (d) the consistent use of single-lumen
PICCs, (e) the consistent use of sutureless devices, (f) the
prevalent use of a PICC of relatively small diameter (i.e.,
4 Fr), and (g) the consistent control of the position of the
catheter tip, with reposition of the catheter if the tip of the
PICC was not at the appropriate location. Indeed, data from
literature demonstrated that the risk of thrombosis decreased
when PICCs were placed according to this decision-making
[31, 43, 45]. Moreover, our study was not designed to inves-
tigate the incidence of asymptomatic thrombosis; thus, the
incidence most likely would have been higher if our patients
systematically had been explored using ultrasound.
On the whole, the reasons for discrepancies between re-
ported rates of PICC-related complications are not clearly
known, but may include advances in catheter materials, se-
curement devices, and insertion technique; differences in pa-
tient populations (e.g., non- and cancer patients, in- and out-
patients); and design (e.g., retrospective vs. prospective) and
methodological limitations of some of the studies (e.g., earlier
experiences, small-size samples, different definitions of
complications).
Table 3 Characteristics of patients with a PICC dwell time longer than 2 years
Case 1 Case 2 Case 3 Case 4 Case 5 Case 6 Case 7
Gender Female Female Female Male Female Female Male
Agea (years) 65 58 49 53 60 63 56
Tumor site Pancreas Ovary Stomach Rectum Oral cavityb Stomach Stomach
Stagea III II IV II II II III
Karnofsky PSa 70 70 70 80 80 80 70
CRPa, mg/l 1.2 9.3 0.4 8.7 9.7 9.1 2.1
Albumina, g/dl 4.6 3.1 4.2 4.3 4.7 3.6 3.7
Body mass indexa 22.2 21.3 14.5 23.9 21.1 21.1 20.9
Hospital (days)c, n 141 122 61 29 105 16 46
Operationc, n 2 1 0 1 5 0 0
Chemotherapyc, cycles 6 12 12 3 2 4 12
Radiation therapyc Yes No No Yes Yes No No
HPN daysc, n 639 724 791 586 1,268d 1,139 788d
Catheter days, n 790 763 824 782 1,384d 1,154 802d
Catheter complications No No No No No Yese No
PICC removal Yesf Yesf Yesf Yesg No Yesf No
PICC peripherally inserted central catheter, PS performance status, CRP C-reactive protein, HPN home parenteral nutrition
a At the time of PICC insertion
b Percutaneous endoscopic and radiologic gastrostomy not feasible
c After PICC insertion
dOn February 28, 2014
e Lumen occlusion due to clots occurred after 953 catheter days and was successfully treated by infusing urokinase
f Cause: death
g Cause: end of HPN
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Anecdotally, in this paper was reported a case series of
seven patients with a PICC in site for more than 2 years, with
two PICCs lasting more than 3 years. Although these PICCs
were used also in the hospital setting—with a higher risk of
complications than the home setting [42]—as well as for
HPN, chemotherapy, and drawing blood, no infectious com-
plications or thrombosis occurred and the PICCs were not
removed because of complications. Despite the very small
number of cases, it seems that PICCs, when optimally man-
aged, can be even successfully used for very long periods in
cancer patients requiring a long-term vascular access.
In summary, we believe that three key elements played a
pivotal role to reduce the overall rate of complications and
prolong the PICC life span in our patient population: (a) the
availability of a knowledgeable and experienced central ve-
nous access team; (b) the use of ultrasound-guided venipunc-
ture; and (c) a proper patients’ education and a specific care-
givers’ training, along with close monitoring by trained nurses
at home.
Strengths and limitations of the study
To the best of our knowledge, this is the largest study reporting
catheter-related complications in a case series of non-hospitalized
cancer patients with 269 PICCs used for chemotherapy and/or
HPN for a long period (5 years and over 55,000 catheter days). If
compared with previous studies in this field, our study has some
relevant and original features: (1) data were collected through a
clinical study and not from a database, registry, or questionnaire;
(2) it was a prospective study; (3) only cancer patients were
enrolled; (4) only outpatients were enrolled; (5) most of the
enrolled patients (71 %) were receiving chemotherapy during
the course of the study; (6) all PICCswere insertedwith the same
evidence-based protocol and all patients received the same
evidence-based protocol of maintenance/care at home; (7) the
median dwell time for PICCs was very long (more than
6 months); and (8) no patient was lost at follow-up.
Our study presented several limitations. First, this was a
single-center study carried out by teams with a well-
established experience in PICC placement and home manage-
ment, as well as a well-defined collaboration with the oncol-
ogists. Second, in this study, almost all patients with solid
tumors were enrolled; therefore, our results may not be ex-
tended to all cancer patients (e.g., hematological malignan-
cies). Third, only non-hospitalized cancer patients receiving
chemotherapy and/or HPN—always assisted at home by
trained caregivers and specifically trained nurses—were in-
cluded. Therefore, because this is a small subset of cancer
patients, our results may not be generalizable to inpatient
populations or different outpatient settings (e.g., patients re-
ceiving chemotherapy alone). Fourth, patient-related factors,
such as impingement on quality of life and cost of VAD
maintenance, have not been explored in this study. Finally,
this was an observational study, and a trial comparing PICCs
with well-defined long-term VADs (i.e., tunneled catheters
and ports) needs to be carried out to recommend the use of
PICCs as long-termVADs in non-hospitalized cancer patients.
Despite several limitations, our study suggests that PICCs
can be successfully utilized as safe and long-lasting VADs in
non-hospitalized cancer patients recording a low and accept-
able incidence of overall complications.
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